Cardiac Bypass and Ventricular Assist Devices/ECMO

  • Thomas G. DeLougheryEmail author


This chapter discussed cardiac bypass – origin of associated coagulation defects, preparing the patient for surgery, and management of bleeding. Issues with ventricular assist devices will also be discussed.


Coronary artery bypass Ventricular assist device Antifibrinolytic Argatroban Bivalirudin 

Suggested Reading

  1. Baumann Kreuziger LM, Kim B, Wieselthaler GM. Antithrombotic therapy for left ventricular assist devices in adults: a systematic review. J Thromb Haemost. 2015;13(6):946–55.CrossRefGoogle Scholar
  2. Davidson S. State of the art – how i manage coagulopathy in cardiac surgery patients. Br J Haematol. 2014;164(6):779–89.CrossRefGoogle Scholar
  3. Doyle AJ, Hunt BJ. Current understanding of how extracorporeal membrane oxygenators activate haemostasis and other blood components. Front Med (Lausanne). 2018;5:352.CrossRefGoogle Scholar
  4. Muslem R, Caliskan K, Leebeek FWG. Acquired coagulopathy in patients with left ventricular assist devices. J Thromb Haemost. 2018;16(3):429–40.CrossRefGoogle Scholar
  5. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, Cooper DJ, Marasco S, McNeil J, Bussières JS, McGuinness S, Byrne K, Chan MT, Landoni G, Wallace S, ATACAS Investigators of the ANZCA Clinical Trials Network. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med. 2017;376(2):136–48.CrossRefGoogle Scholar
  6. Raffini L. Anticoagulation with VADs and ECMO: walking the tightrope. Hematology Am Soc Hematol Educ Program. 2017;2017(1):674–80. Scholar
  7. Ranucci M. Hemostatic and thrombotic issues in cardiac surgery. Semin Thromb Hemost. 2015;41(1):84–90.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Hematology/Medical Oncology, Department of Medicine, Pathology, and PediatricsOregon Health & Sciences UniversityPortlandUSA

Personalised recommendations